NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2071210008

Registered date:09/04/2021

A phase 1 mass balance study of [14C]TAS-205 in healthy volunteers

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedDuchenne Muscular Dystrophy
Date of first enrollment24/05/2021
Target sample size6
Countries of recruitment
Study typeInterventional
Intervention(s)Orally administer 80 mL of the liquid containing [14C]TAS-205 and TAS-205 on day 1.

Outcome(s)

Primary Outcome- Concentrations of total radioactivity in blood and plasma, plasma TAS-205 concentrations and the pharmacokinetics parameters of TAS-205 - Radioactivity excretion and excretion rate, cumulative excretion, cumulative excretion rate into urine and feces. - Radioactivity excretion and excretion rate, cumulative excretion, cumulative excretion rate in all excreta (urine and faeces). - Plasma, urinary, and fecal metabolite profiles of TAS-205 , and structural estimation.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum< 40age old
GenderBoth
Include criteria(1) Healthy adult male subjects who provided written informed consent to participate in the study (2) Aged 20 years or older and younger than 40 years at the time of informed consent (3) Capable of oral intake. (4) Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0
Exclude criteria(1) Had current or previous hypersensitivity or allergy to drugs (2) Had current or previous drug abuse (including use of illicit drugs) or alcoholism (3) Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded) (4) Consumed foods or beverages containing the St. John's Wort within 28 days before study drug administration (5) Had blood pressure, pulse rate, and body temperature meeting any of the following at screening: Systolic blood pressure: <90 mmHg or >=140 mmHg Diastolic blood pressure: <40 mmHg or >=90 mmHg Pulse rate: <40 beats per minute (bpm) or >=100 bpm Body temperature: 35.0 or >= 37.1

Related Information

Contact

Public contact
Name Yoshitaka Takebe
Address 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo Tokyo Japan 101-8444
Telephone +81-3-3293-2455
E-mail y-takebe@taiho.co.jp
Affiliation Taiho Pharmaceutical Co., Ltd.
Scientific contact
Name Ali Nasermoaddeli
Address 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo Tokyo Japan 101-8444
Telephone +81-3-3293-2455
E-mail y-takebe@taiho.co.jp
Affiliation Taiho Pharmaceutical Co., Ltd.